This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients | MicrobiomeTrials
← Back to trials NCT06306014
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-05-07Est. Completion: 2028-01-07
Enrollment target: 56 participantsLocations CH Annecy Genevois Service de Maladies infectieuses, Annecy, France Service d'hépato-gastroentérologie - CHU Estaing, Clermont-Ferrand, France CHU Grenoble Service Maladies infectieuses et tropicales, Grenoble, France CHU Lille Unité des Maladies Infectieuses et tropicales, Lille, France Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse, Lyon, France APHM La Timone Service de Maladies infectieuses, Marseille, France Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP), Paris, France Service d'infectiologie - Hôpital Nord / CHU Saint Etienne, Saint-Etienne, France Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse, Toulouse, France Service de Maladies Infectieuses - CH de Valence, Valence, France Other microbiome trials you might be interested in Clostridium Difficile Infection
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose …
Knoxville, United States Est. completion Aug 22, 2028
Neutropenia, Febrile
The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection i…
Leuven, Belgium Completed Mar 8, 2026
Blood Stream Infections Ventilator Associated Pneumonia Healthcare Associated Infection Carbapenem-Resistant Enterobacteriaceae Infection Hospital-acquired Pneumonia
RAPID is an investigator initiated Phase 4, multinational, multicentre, open-label, randomised controlled superiority tr…
Vellore, India Est. completion Oct 31, 2027